Howland Capital Management LLC Has $463,000 Stake in NeoGenomics, Inc. (NASDAQ:NEO)

Howland Capital Management LLC cut its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 30.5% during the 1st quarter, Holdings Channel reports. The firm owned 29,454 shares of the medical research company’s stock after selling 12,936 shares during the quarter. Howland Capital Management LLC’s holdings in NeoGenomics were worth $463,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Burkett Financial Services LLC acquired a new position in shares of NeoGenomics in the fourth quarter valued at $46,000. Quadrant Capital Group LLC grew its stake in NeoGenomics by 22.0% in the 4th quarter. Quadrant Capital Group LLC now owns 4,900 shares of the medical research company’s stock valued at $79,000 after buying an additional 883 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in NeoGenomics by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,434 shares of the medical research company’s stock valued at $136,000 after buying an additional 1,791 shares during the last quarter. Banque Cantonale Vaudoise grew its stake in NeoGenomics by 6.6% in the 1st quarter. Banque Cantonale Vaudoise now owns 15,942 shares of the medical research company’s stock valued at $251,000 after buying an additional 993 shares during the last quarter. Finally, White Pine Capital LLC acquired a new position in NeoGenomics in the 4th quarter valued at about $261,000. 98.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Needham & Company LLC decreased their price target on shares of NeoGenomics from $24.00 to $19.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. BTIG Research decreased their price target on shares of NeoGenomics from $23.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday, May 2nd. Craig Hallum began coverage on shares of NeoGenomics in a report on Wednesday, May 1st. They issued a “buy” rating and a $26.00 price objective for the company. Benchmark reissued a “buy” rating and issued a $18.00 price objective on shares of NeoGenomics in a report on Wednesday, May 1st. Finally, TD Cowen cut their price objective on shares of NeoGenomics from $21.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.78.

NeoGenomics Stock Performance

NASDAQ NEO opened at $14.47 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.48 and a quick ratio of 7.22. NeoGenomics, Inc. has a twelve month low of $11.03 and a twelve month high of $21.22. The business’s fifty day moving average is $14.01 and its 200 day moving average is $14.88.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). NeoGenomics had a negative net margin of 13.79% and a negative return on equity of 3.54%. The firm had revenue of $156.24 million for the quarter, compared to analyst estimates of $149.82 million. Equities analysts predict that NeoGenomics, Inc. will post -0.21 earnings per share for the current fiscal year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.